<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="13" ids="22720">benzodiazepine</z:chebi>, midazolam, is commonly used for sedation and anesthesia in the operating room and the intensive care unit where there is a risk of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore examined its ability to reduce damage subsequent to <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Male Wistar rats were randomly assigned to a high-dose midazolam group or a matched vehicle group and a lower dose of midazolam group or a matched vehicle group </plain></SENT>
<SENT sid="3" pm="."><plain>The rats underwent 90 minutes of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In the midazolam groups, the first dose of midazolam (10 or 25 mg/kg) was given by a 10-minute intravenous infusion before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>; a second dose of (1/2) the initial dose (5 or 12.5 mg/kg) was given 1 hour after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In the vehicle groups, a similar volume of vehicle was given at the same time intervals </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size, NeuN immunopositive cells in the ischemic penumbral and core regions, and neurologic outcome were determined 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with vehicle-treated rats, the higher-dose midazolam (25 mg/kg)-treated rats had a smaller <z:mpath ids='MPATH_124'>infarct</z:mpath> size (93.9+/-63.5 mm vs. 152.0+/-53.7 mm, P&lt;0.05), more NeuN immunopositive cells in the ischemic core region (206.7+/-211.3/mm vs. 40.0+/-66.3/mm, P&lt;0.01), and better neurologic outcome (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Midazolam at a lower dose (10 mg/kg) had no significant effects </plain></SENT>
<SENT sid="9" pm="."><plain>Although midazolam generated dose-dependent <z:mp ids='MP_0010163'>hemolysis</z:mp>, this <z:mp ids='MP_0010163'>hemolysis</z:mp> was transient </plain></SENT>
<SENT sid="10" pm="."><plain>Midazolam (25 mg/kg) caused a loss of the righting reflex in rats that lasted until 19.9+/-1.3 min after the injection, the <z:chebi fb="164" ids="38867">anesthetic</z:chebi> dose of midazolam in rats is approximately 100x greater than the <z:chebi fb="164" ids="38867">anesthetic</z:chebi> dose for humans </plain></SENT>
<SENT sid="11" pm="."><plain>An <z:chebi fb="164" ids="38867">anesthetic</z:chebi> dose of midazolam in rats reduced neuronal damage and improved neurologic outcome 7 days after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, however, it also caused transient <z:mp ids='MP_0010163'>hemolysis</z:mp> </plain></SENT>
</text></document>